CompuMed (OTCMKTS:CMPD) vs. InterCure (NASDAQ:INCR) Head to Head Comparison

InterCure (NASDAQ:INCR) and CompuMed (OTCMKTS:CMPD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for InterCure and CompuMed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1	0	0	0	1.00
CompuMed	0	0	0	0	0.00

Risk and Volatility

InterCure has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, CompuMed has a beta of -0.35, indicating that its share price is 135% less volatile than the S&P 500.

Valuation & Earnings

This table compares InterCure and CompuMed”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$64.55 million	N/A	-$18.32 million	$0.08	11.57
CompuMed	$7.55 million	0.75	-$60,000.00	($0.05)	-85.20

CompuMed has lower revenue, but higher earnings than InterCure. CompuMed is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares InterCure and CompuMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
CompuMed	-0.85%	-1.90%	-1.29%

Insider and Institutional Ownership

8.3% of InterCure shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 22.0% of CompuMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

InterCure beats CompuMed on 9 of the 11 factors compared between the two stocks.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

About CompuMed

CompuMed, Inc., an enterprise telemedicine solutions company, provides clinical care services for patients and medical facilities. It offers telecardiology and teleradiology services that provide real-time access to U.S. Board-Certified specialists through cloud-based technology and integrated medical devices to medical facilities worldwide. The company also provides enterprise telemedicine solutions; a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including electrocardiogram (ECG) devices, echocardiogram, ECG, vascular, holter, nuclear, and video consults; and reading, transcription, reporting, storage, and video consultations in the areas of Vscan, X-ray, ultrasound, mammography, computed tomography, magnetic resonance imaging, and radiologist video consults. It also offers OsteoGram software that works in combination with standard or digital X-ray equipment to support osteoporosis screening, diagnosis, and therapy monitoring. In addition, the company provides mobile ECG and ultrasound solutions that provide patients with immediate access to its board-certified specialists; and medical devices. It serves organ procurement organizations, rural healthcare, and correctional healthcare industries. CompuMed, Inc. was founded in 1973 and is headquartered in Los Angeles, California.